Efficacy and Safety of 14-day Concomitant Therapy for Difficult-to-Treat Helicobacter Pylori Infection
Status:
Not yet recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate efficacy of a 14-day concomitant therapy for the
third-line treatment of Hard-to-treat Helicobacter pylori infection, and whether it is safe
while maintaining an ideal eradication rates